The American Journal of Managed Care December 2010
"Under the Radar": Nurse Practitioner Prescribers and Pharmaceutical Industry Promotions
Nurse practitioner prescribers exhibited a high rate of contact with pharmaceutical industry promotional activities.
Our analysis has some limitations. The study had a low response rate, affecting generalizability of our findings. However, online surveys have been noted to have low response rates, especially among healthcare professionals.21 Also, our results demonstrated convergent validity with other comparable NP research performed during the same period relative to response rate, educational level, clinical specialty, practice setting, and respondent sex.22
In conclusion, NPs have heretofore been operating “under the radar” regarding research and policy on the influences of pharmaceutical marketing. Although the scope and extent of their prescribing activities have been less than obvious to consumers and to other healthcare professionals, the pharmaceutical industry has clearly taken notice. According to the pharmaceutical research company Verispan23 (now SDI, Plymouth Meeting, Pennsylvania), a 20% increase in marketing between 2004 and 2006 was directed to NPs and other nonphysician prescribers. This is striking considering the substantial number of NPs and their growing role in the delivery of primary healthcare in the United States. Therefore, it is important that all prescribers, including NPs, have access to unbiased information that is not underwritten by industry. Future research should assess influences of evidence-based academically sponsored continuing education programs on NP prescribers’ beliefs and practices.
We thank Melissa Maloney, MS, RN, and Marion Rideout, MS, RN, for their support with initial literature review and data evaluation. We also thank Dr Anthony Guarino for his input on statistical content.
Author Affiliations: From MGH Institute of Health Professions, School of Nursing (ECL, DFM), Boston, MA; Department of General Medicine (SE), Brigham & Women's Hospital, Boston, MA; and Department of Medicine (SE), Harvard Medical School, Boston, MA.
Funding Source: This study was funded by the Attorney General Consumer and Prescriber Grant Program.
Author Disclosures: The authors (ECL, DFM, SE) report no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this article.
Authorship Information: Concept and design (ECL, DFM); acquisition of data (ECL); analysis and interpretation of data (ECL, DFM, SE); drafting of the manuscript (ECL, DFM, SE); critical revision of the manuscript for important intellectual content (ECL, DFM, SE); statistical analysis (DFM, SE); obtaining funding (ECL); administrative, technical, or logistic support (ECL); and supervision (ECL).
Address correspondence to: Elissa C. Ladd, PhD, RN, FNP-BC, MGH Institute of Health Professions School of Nursing, 36 First Ave, Boston, MA 02129. E-mail: firstname.lastname@example.org.
1. Fischer MA, Keough ME, Baril JL, et al. Prescribers and pharmaceutical marketing: why are we still meeting? J Gen Intern Med. 2009;24(7):795-801.
2. Avorn J, Solomon DH. Cultural and economic factors that (mis) shape antibiotic use: the nonpharmacologic basis of therapeutics. Ann Intern Med. 2000;133(2):128-135.
3. Chren MM, Landefeld CS. Physicians' behavior and their interactions with drug companies: a controlled study of physicians who requested additions to a hospital drug formulary. JAMA. 1994;271(9):684-689.
4. Crigger N, Barnes K, Junko A, Rahal S, Sheek C. Nurse practitioners' perceptions and participation in pharmaceutical marketing. J Adv Nurs. 2009;65(3):525-533.
5. Ladd E. The use of antibiotics for upper respiratory tract infections: an analysis of nurse practitioner and physician prescribing practices in ambulatory care, 1997-2001. J Am Acad Nurse Pract. 2005;17(10):416-424.
6. Muncy-Blunt E. The influence of pharmaceutical company sponsored educational programs, promotions and gifts on the self-reported prescribing beliefs and practices of certified nurse practitioners in three states [Drexel theses and dissertations]. March 17, 2005. http://hdl.handle.net/1860/435. Accessed October 23, 2010.
7. Lurie N, Rich EC, Simpson DE, et al. Pharmaceutical representatives in academic medical centers: interaction with faculty and housestaff. J Gen Intern Med. 1990;5(3):240-243.
8. Steinman MA, Shlipak MG, McPhee SJ. Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. Am J Med. 2001;110(7):551-557.
9. Health Resources and Services Administration, US Department of Health and Human Services. The registered nurse population: initial findings from the 2008 National Sample Survey of Registered Nurses. March 2010. http://bhpr.hrsa.gov/healthworkforce/rnsurvey/initialfindings2008.pdf. Accessed August 4, 2010.
10. American Academy of Family Physicians. State-by-state number of family physicians in 2006 and projected need in 2020. Updated 2006. http://www.aafp.org/online/etc/medialib/aafp_org/documents/press/ charts-and-graphs/family-physicians-state-by-state.Par.0001.File.tmp/ st-by-st-need.pdf. Accessed August 7, 2009.
11. Cooper RA. Health care workforce for the twenty-first century: the impact of nonphysician clinicians. Annu Rev Med. 2001;52:51-61.
12. Bacchetta S, Green R. Underwriters: the importance of nurse practitioners and physician assistants. August 2007. http://www.sallybacchetta.com/articles_13.htm. Accessed October 23, 2010.
13. Katz D, Caplan AL, Mertz JF. All gifts large and small: toward an understanding of the ethics of pharmaceutical industry gift-giving. Am J Bioeth. 2003;3(3):39-46.
14. Adair RF, Holmgren LR. Do drug samples influence resident prescribing behavior? a randomized trial. Am J Med. 2005;118(8):881-884.
15. Cutrona SL, Woolhandler S, Lasser KE, Bor DH, McCormick D, Himmelstein DU. Characteristics of recipients of free prescription drug samples: a nationally representative analysis. Am J Public Health. 2008;98(2):284-289.
16. Rothman DJ, McDonald WJ, Berkowitz CD, et al. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA. 2009;301(13):1367-1372.
17. Council on Ethical and Judicial Affairs, American Medical Association. CEJA report 1-A-09: financial relationships with industry in continuing medical education. June 5, 2009. http://www.ama-assn.org/ama1/pub/upload/mm/475/ceja0109.pdf. Accessed October 23, 2010.
18. Morris L, Taitsman JK. The agenda for continuing medical education: limiting industry's influence. N Engl J Med 2009;361(25): 2478-2482.
19. Committee on Planning a Continuing Health Professional Education Institute, Institute of Medicine. Redesigning Continuing Education in the Health Professions. Washington, DC: National Academies Press; 2010. http://www.nap.edu/catalog/12704.html. Accessed December 16, 2009.
20. AAMC Government Relations, American Association of Medical Colleges. Physician payment sunshine provisions in health care reform. Summary March 30, 2010. http://www.aamc.org/reform/summary/ sunshinesummary04022010.pdf. Accessed June 29, 2010.
21. Aitken C, Power R, Dwyer R. A very low response rate in an on-line survey of medical practitioners. Aust N Z J Public Health. 2008;32(3):288-289.
22. Goolsby MJ. 2008 AANP National NP Compensation Survey. J Am Acad Nurse Pract. 2009;21(3):186-188.
23. Verispan. Verispan Personal Selling Audit, Hospital Personal Selling Audit, and Nurse Practitioner/Physician Assistant Audit. Yardley, PA: Verispan LLC; 2007.